Vibliome is developing a new family of therapeutics for the treatment of cancer, contraception and other indications, based upon a novel, focused library of inhibitors of validated and promising kinase targets and their escape pathways.

Robert Goodwin, PhD

Chief Executive Officer
robert.goodwin@vibliome.com

Gary Flynn, PhD

President & Chief Scientific Officer
gary.flynn@vibliome.com